{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:19:23Z","timestamp":1794745163124,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007108","name":"Korea Advanced Institute of Science and Technology Institute for Information Technology Convergence","doi-asserted-by":"publisher","award":["26E0271"],"award-info":[{"award-number":["26E0271"]}],"id":[{"id":"10.13039\/501100007108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119989","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:23:09Z","timestamp":1792218189000},"page":"119989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and preclinical characterization of an MMAE-conjugated anti-EpCAM antibody\u2013drug conjugate for colorectal cancer"],"prefix":"10.1016","volume":"204","author":[{"given":"Hae Li","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qui Ngoc Sang","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Eun","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Beom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Heon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Bhum","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok-Hoon","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wook-Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2026.119989_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bjc.6603494","article-title":"EpCAM (CD326) finding its role in cancer","volume":"96","author":"Baeuerle","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2026.119989_bib2","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.bbamem.2013.04.018","article-title":"EpCAM: structure and function in health and disease","volume":"1828","author":"Schnell","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.biopha.2026.119989_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ncb1824","article-title":"Nuclear signalling by tumour-associated antigen EpCAM","volume":"11","author":"Maetzel","year":"2009","journal-title":"Nat. Cell. Biol."},{"issue":"28","key":"10.1016\/j.biopha.2026.119989_bib4","doi-asserted-by":"crossref","first-page":"24947","DOI":"10.18632\/oncotarget.4453","article-title":"An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer","volume":"6","author":"Liao","year":"2015","journal-title":"Oncotarget"},{"issue":"34","key":"10.1016\/j.biopha.2026.119989_bib5","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1038\/sj.onc.1207610","article-title":"The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation","volume":"23","author":"Munz","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biopha.2026.119989_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semcdb.2008.11.002","article-title":"The \"a disintegrin and metalloprotease\" (ADAM) family of sheddases: physiological and cellular functions","volume":"20","author":"Reiss","year":"2009","journal-title":"Semin. Cell. Dev. Biol."},{"key":"10.1016\/j.biopha.2026.119989_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2407-6-165","article-title":"Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker","volume":"6","author":"Stoecklein","year":"2006","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2026.119989_bib8","first-page":"833","article-title":"A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer","volume":"18","author":"Bokemeyer","year":"2015","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2026.119989_bib9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000318055","article-title":"Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy","volume":"85","author":"Marschner","year":"2010","journal-title":"Urol. Int."},{"issue":"9","key":"10.1016\/j.biopha.2026.119989_bib10","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/annonc\/mdr625","article-title":"Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer","volume":"23","author":"Schmidt","year":"2012","journal-title":"Ann. Oncol."},{"issue":"47","key":"10.1016\/j.biopha.2026.119989_bib11","doi-asserted-by":"crossref","first-page":"39449","DOI":"10.1074\/jbc.M112.386235","article-title":"Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer","volume":"287","author":"Lin","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119989_bib12","doi-asserted-by":"crossref","DOI":"10.1021\/acs.bioconjchem.6c00121","article-title":"A cathepsin B-cleavable self-immolative linker for the delivery of hydroxyl-containing payloads in antibody-drug conjugates","author":"Li","year":"2026","journal-title":"Bioconjug Chem."},{"issue":"37","key":"10.1016\/j.biopha.2026.119989_bib13","doi-asserted-by":"crossref","first-page":"9378","DOI":"10.1039\/D6CC00388E","article-title":"Endogenous stimuli-responsive intelligent drug delivery systems: recent advances in cleavable linker design","volume":"62","author":"Li","year":"2026","journal-title":"Chem. Commun. (Camb. )"},{"issue":"5","key":"10.1016\/j.biopha.2026.119989_bib14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1021\/acsmedchemlett.5c00644","article-title":"Exatecan payload-based antibody-drug conjugates with a short hydrophilic cleavable linker","volume":"17","author":"Jammalamadaka","year":"2026","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2026.119989_bib15","article-title":"Long term survival with trastuzumab deruxtecan for heavily pretreated, HER2 mutated advanced non-small cell lung cancer","author":"Wang","year":"2026","journal-title":"Discov. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119989_bib16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1517\/14712598.2010.482098","article-title":"Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside","volume":"10","author":"Kurtz","year":"2010","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2026.119989_bib17","article-title":"Sacituzumab govitecan as an effective strategy for sensitizing chemoresistant HNSCC cells to senolytic intervention","author":"Luffman","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2026.119989_bib18","article-title":"Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma","author":"Lee","year":"2026","journal-title":"medRxiv"},{"issue":"6","key":"10.1016\/j.biopha.2026.119989_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/03008916251362021","article-title":"Sequential therapy of metastatic urothelial cancer with monomethyl auristatin E (MMAE)-containing antibody-drug conjugates for different targets","volume":"111","author":"Yang","year":"2025","journal-title":"Tumori"},{"key":"10.1016\/j.biopha.2026.119989_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bas.2025.104186","article-title":"Letter to the editor regarding the response to \"Multidisciplinary consensus-based statement on the current role of Middle Meningeal Artery embolization (MMAE) in chronic SubDural Hematoma (cSDH)\"","volume":"5","author":"Foppen","year":"2025","journal-title":"Brain Spine"},{"issue":"3","key":"10.1016\/j.biopha.2026.119989_bib21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/1061186X.2022.2148679","article-title":"EpCAM aptamer activated 5-FU-loaded PLGA nanoparticles in CRC treatment; in vitro and in vivo study","volume":"31","author":"Yavari","year":"2023","journal-title":"J. Drug. Target."},{"issue":"2","key":"10.1016\/j.biopha.2026.119989_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10059-009-0028-9","article-title":"Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity","volume":"27","author":"Yang","year":"2009","journal-title":"Mol. Cells"},{"key":"10.1016\/j.biopha.2026.119989_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/978-1-0716-4591-8_18","article-title":"High-throughput epitope binning analysis of human monoclonal antibodies to assess epitope diversity using the octet bio-layer interferometry platform","volume":"2937","author":"Apiyo","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119989_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1475-2867-10-44","article-title":"Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies","volume":"10","author":"Munz","year":"2010","journal-title":"Cancer Cell. Int."},{"issue":"1","key":"10.1016\/j.biopha.2026.119989_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12985-023-02230-9","article-title":"Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants","volume":"20","author":"Ko","year":"2023","journal-title":"Virol. J."},{"key":"10.1016\/j.biopha.2026.119989_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coi.2021.03.014","article-title":"Conformational sensing of major histocompatibility complex (MHC) class I molecules by immune receptors and intracellular assembly factors","volume":"70","author":"Geng","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2026.119989_bib27","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1038\/ncomms5764","article-title":"Crystal structure and its bearing towards an understanding of key biological functions of EpCAM","volume":"5","author":"Pavsic","year":"2014","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119989_bib28","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1038\/s41598-023-31263-x","article-title":"Characterization of human anti-EpCAM antibodies for developing an antibody-drug conjugate","volume":"13","author":"Satofuka","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119989_bib29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biochi.2020.08.019","article-title":"Antibody stability: a key to performance - Analysis, influences and improvement","volume":"177","author":"Ma","year":"2020","journal-title":"Biochimie"},{"issue":"11","key":"10.1016\/j.biopha.2026.119989_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody-drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.biopha.2026.119989_bib31","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1158\/1535-7163.MCT-24-0087","article-title":"The vedotin antibody-drug conjugate payload drives platform-based nonclinical safety and pharmacokinetic profiles","volume":"23","author":"Neff-LaFord","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119989_bib32","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/jcph.1682","article-title":"Population pharmacokinetics of brentuximab vedotin in adult and pediatric patients with relapsed\/refractory hematologic malignancies: model-informed hypothesis generation for pediatric dosing regimens","volume":"60","author":"Suri","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119989_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/iju5.70270","article-title":"Pseudoprogression during enfortumab vedotin plus pembrolizumab therapy in muscle-invasive bladder cancer achieving pathological complete response: a case report","volume":"9","author":"Nakanishi","year":"2026","journal-title":"IJU Case Rep."},{"issue":"8","key":"10.1016\/j.biopha.2026.119989_bib34","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-026-07067-0","article-title":"Zanubrutinib potentiates polatuzumab vedotin efficacy in DLBCL with concurrent CD79b upregulation","volume":"105","author":"Zhou","year":"2026","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119989_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3892\/ol.2023.13778","article-title":"Clinical significance of the KRAS G13D mutation in anastomotic recurrence of colorectal cancer","volume":"25","author":"Matsunaga","year":"2023","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.biopha.2026.119989_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11306-020-01674-2","article-title":"Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines","volume":"16","author":"Varshavi","year":"2020","journal-title":"Metabolomics"},{"issue":"2","key":"10.1016\/j.biopha.2026.119989_bib37","first-page":"248","article-title":"Preparation and application of patient-derived xenograft mice model of colorectal cancer","volume":"26","author":"Zhang","year":"2023","journal-title":"Iran. J. Basic. Med. Sci."},{"key":"10.1016\/j.biopha.2026.119989_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2022.123715","article-title":"Multi-modal imaging probe for EpCAM overexpressed in breast cancer","volume":"250","author":"Dai","year":"2022","journal-title":"Talanta"},{"issue":"12","key":"10.1016\/j.biopha.2026.119989_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123805","article-title":"Lung adenocarcinoma mouse models based on orthotopic transplantation of syngeneic tumor-initiating cells expressing EpCAM, SCA-1, and Ly6d","volume":"12","author":"Semba","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.biopha.2026.119989_bib40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.46883\/2026.25921071","article-title":"Synchronous endometrial and ovarian cancers: a case study and literature review","volume":"40","author":"Kostrzanowski","year":"2026","journal-title":"Oncology"},{"key":"10.1016\/j.biopha.2026.119989_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1741582","article-title":"Breast and ovarian cancers: toward a multi-cancer early detection test","volume":"17","author":"Habel","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119989_bib42","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.104521","article-title":"Study of high levels of wilms' Tumor 1 (WT1) expression in ovarian cancers","author":"Fatima","year":"2026","journal-title":"Cureus 18(3"},{"issue":"9","key":"10.1016\/j.biopha.2026.119989_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093310","article-title":"Feasibility of imaging EpCAM expression in ovarian cancer using radiolabeled DARPin Ec1","volume":"21","author":"Vorobyeva","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119989_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1515\/med-2017-0007","article-title":"Clinicopathology of EpCAM and EGFR in human epithelial ovarian carcinoma","volume":"12","author":"Zheng","year":"2017","journal-title":"Open. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119989_bib45","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2026.119989_bib46","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","article-title":"Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors","volume":"71","author":"Rudnick","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119989_bib47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.actbio.2019.04.044","article-title":"Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo","volume":"91","author":"Lee","year":"2019","journal-title":"Acta Biomater."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226010255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226010255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:53:54Z","timestamp":1794743634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226010255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":47,"alternative-id":["S0753332226010255"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119989","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and preclinical characterization of an MMAE-conjugated anti-EpCAM antibody\u2013drug conjugate for colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119989"}}